Technology
Biology Technology
Microbix Biosystems Re-files Annual Results With OSC
| 11/6/2009 | TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (the "Company") announces today that it has re-filed the Form 52-109F1 Certification of Annual Filings of William Gastle, the Chief Executive Officer and James Long, the Chief Financial Officer (the "Officer's Certificates") dated January 12, 2009 in connection with the annual audited financial statements for the year ended... [Comments] |
Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
| 11/6/2009 | LYNBROOK, N.Y., Nov. 6 BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommend... [Comments] |
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
| 11/6/2009 | AURORA, Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading produ... [Comments] |
| 11/6/2009 | QUINCY, Mass., Nov. 6 Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myria... [Comments] |
| 11/6/2009 | VIENNA, Austria, November 6 EUCODIS Bioscience, a companydeveloping, customizing, manufacturing, and marketing enzymes for thechemical industry announced today that it has entered into a researchagreement with Bio Sidus, the leading biopharmaceutical company in LatinAmerica. The agreement gives EUCODIS Bioscience exclusive access - for the searchof enzym... [Comments] |
NeurogesX Reports Third Quarter 2009 Results
| 11/6/2009 | SAN MATEO, Calif., Nov. 6 3Q09 Corporate Highlights: Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd. Made significant progress in commercial readiness activities Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations Appointed Bradford S. Good... [Comments] |
| 11/6/2009 | SPRING VALLEY, Calif., Nov. 6 Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus. Dengue virus is a mosquito-born flavivir... [Comments] |
| 11/6/2009 | CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.... [Comments] |
| 11/6/2009 | HAYWARD, Calif., Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA: (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) Continuous Subcutaneous Deliver... [Comments] |
| 11/6/2009 | The agenda for Arrowhead’s 2010 Personalized Medicine Partnerships Conference, which is set to take place on February 22-24, 2010 in Philadelphia, has been announced. At this three day conference we will highlight key issues in forming partnerships and engage the best speakers to share their experiences. Minneapolis, MN (PRWEB) November... [Comments] |
November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory
| 11/5/2009 | TRANSPORTATION -- Gone hybrid . . . Fuel economy ratings for the new 2010 model year automobiles are now posted at the www.fueleconomy.gov web site, which Oak Ridge National Laboratory developed and maintains for the U.S. Department of Energy and the U.S. Environmental Protection Agency. Nine of the top 10 vehicles on the best fuel economy list are hybrid electrics, led by the Toyot... [Comments] |
Medicine Technology
SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
| 11/6/2009 | BOTHELL, Wash., Nov. 6 SCOLR Pharma, Inc. (Amex: DDD ) today reported financial results for the three and nine months ended September 30, 2009. Stephen J. Turner, SCOLR Pharma's President and CEO, said, "We continue to advance discussions related to licensing our 12-hour ibuprofen formulation. Several potential partners have committed significant resource... [Comments] |
Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
| 11/6/2009 | DURHAM, N.C., Nov. 6 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that a previously approved reverse split of its common stock will take effect at the start of trading on Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted basis. Oxygen Biotherapeutics, Inc. shares will trade under the new symbol OXBT. The stock also will have a new CUSIP... [Comments] |
Recession Continues to Depress Sales at Allied Healthcare Products
| 11/6/2009 | ST. LOUIS, Nov. 6 Recession in domestic and international markets continued to depress sales for Allied Healthcare Products in the first quarter of fiscal year 2010 ending September 30, 2009. Sales declines pushed Allied into a loss for the quarter. The net loss for the quarter was about $745,000, or negative 9 cents per share, compared to a net profit the... [Comments] |
| 11/6/2009 | FORT WASHINGTON, Pa., Nov. 6 In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is initiating a voluntary recall of a limited number of product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP. McNeil is initiating the recall after identifyin... [Comments] |
DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
| 11/6/2009 | WILMINGTON, Mass., Nov. 6 DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curha... [Comments] |
Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
| 11/6/2009 | SAN DIEGO, Nov. 6 Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company. Credit Suisse Securities (USA) LL... [Comments] |
Watson to Present at Credit Suisse Healthcare Conference
| 11/6/2009 | MORRISTOWN, N.J., Nov. 6 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, 2009 at 12:00 pm Eastern St... [Comments] |
Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results
| 11/6/2009 | OAKLAND, Calif., Nov. 6 Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals (KFHP/H), and their subsidiaries reported today a combined total operating revenue of $10.5 billion for the quarter ended September 30, 2009, compared to $10.2 billion in the third quarter of last year. Operating income in the third quarter was $336 million, compared to $307 million in... [Comments] |
NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009
| 11/6/2009 | WESTBURY, N.Y., Nov. 6 Repossessions and liquidations of trucking equipment and machine tools in the third quarter of 2009 declined as compared to similar figures from 2008, according to Nassau Asset Management's NasTrac Quarterly Index (NQI). The figures, culled from the company's activity reports for both repossessions and orderly liquidations, also indicated a rise in r... [Comments] |
| 11/6/2009 | SARASOTA, Fla., Nov. 6 Roper Industries, Inc. (NYSE: ROP) today announced that it has signed a definitive agreement to acquire Verathon, Inc., a leading provider of proprietary medical devices. The Verathon Board of Directors has approved the transaction and the closing is subject to customary regulatory approvals and closing conditions, including shareholder... [Comments] |
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
| 11/6/2009 | DETROIT, Nov. 6 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® ophthalmic solution on the first day following patent expiration. This s... [Comments] |
(Date:11/6/2009)...re-FirstCall/ -- BioSpecifics Technologies Corp. (...oping first-in-class collagenase-based products, t... quarter ended September 30, 2009. ,, "We were...the FDA,s Arthritis Advisory Committee unanimously...IAFLEX(TM) for the treatment of Dupuytren,s diseas...
(Date:11/6/2009)...swire-FirstCall/ -- ,, 3Q09 Corporate Highli....U. Marketing Authorization to Astellas Pharma Eur... readiness activities Expanded management team to... Director, Commercial Operations Appointed Bradfo...ttee chairman , Upcoming 2009 Milestones: ...
(Date:11/6/2009)...or Arrowhead’s 2010 Personalized Medicine Pa...on February 22-24, 2010 in Philadelphia, has been ...ghlight key issues in forming partnerships and eng... , Minneapolis, MN (PRWEB)...o;s 2010 Personalized Medicine Partnerships Confe...
(Date:11/5/2009)...wire/ -- DSM Pharmaceutical Products today announc...Galenix, Saint Jean D,Illac, France, where DSM wil...partner for Galenix commercial products on a globa... business development opportunities co-marketing G...rength of Galenix in drug product development and ...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3[0] Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results[0] NeurogesX Reports Third Quarter 2009 Results[0] Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference[0] DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix
...son, Wis. - The growing body of university resea...University of Wisconsin-Madison could grow at an ...ocation approved Friday by University of Wisconsin...rch Foundation. , ,The grant will provide funding...tem schools. The focus, however, extends beyond th...
...son, Wis. - A Madison-based company experienced i...eceive $150,000 from Congress to help finance a bi...k Incubator was included at the request of U.S. R...s bill passed Wednesday in the House of Representa...e, and the final version must be signed by Preside...
...son, Wis. - Madison Development Corp. has close...s, Extract Systems, LLC , and Universal Separato... , ,The funds are part of a Venture Debt Fund est...fit development company serving hard-to-finance sm...tems will help the company market its data extract...
Other Biology Technology:WiSys to distribute $1 million in research funds 2WiSys to distribute $1 million in research funds 3WiSys to distribute $1 million in research funds 4Baldwin backs funding for Midwest biotech incubator 2MDC provides venture funding for tech companies 2(Date:11/6/2009)... N.Y., Nov. 6 Repossessions and li... in the third quarter of 2009 declined as compared... Asset Management,s NasTrac Quarterly Index (NQI)....reports for both repossessions and orderly liquida...both construction and printing equipment, offering...
(Date:11/6/2009)..., N.J., Nov. 6 Derma S...ider of advanced wound care products, announced pl...re market on Monday, November 16, 2009. The Compan...cuss the results at 11:00 am EST. Interested parti...350-1684 (international), with passcode 81416481 t...
(Date:11/6/2009)...LE, Pa., Nov. 6 Philips Respironic...Control and Prevention (CDC) to raise awareness ab...eep insufficiency. The CDC,s release of the first-...fferences in sleeplessness is a milestone in quant...s a long-time educator, industry leader and sleep ...
Breaking Medicine Technology:NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Scientists Spot How Sugar Feeds Tumors 54950 1MN Community Measurement Launches First Of Its Kind Quality Measure For Depression Care 54948 1MN Community Measurement Launches First Of Its Kind Quality Measure For Depression Care 54948 2MN Community Measurement Launches First Of Its Kind Quality Measure For Depression Care 54948 3STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 1STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 2STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 3STAAR Surgical Reports Progress on Japanese Application for Approval of Visian 28TM 29 Implantable Collamer 28R 29 Lens 28ICL 28TM 29 29 54946 4[0] NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009[0] Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call[0] Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation
...0 Valor Medical, an emerging medical,device compa...t human,implant of Neucrylate AN for treatment of ...z at the University of Tehran. The treatment was u...been approved by the University,s,Internal Ethics ...aneurysm was a type and location,that is very diff...
...FluoroPharma Inc., a company,developing breakthrou...,Positron Emission Tomography (PET) market, announ...PET, following institutional review board (IRB),ap...is a single center,open label study, designed to e...T as a PET tracer for myocardial perfusion imaging...
Other Medicine Technology:FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |